Novavax (NVAX) – Globe Newswire
-
Shah Capital nominates two highly qualified independent director candidates for Novavax
-
Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Snap, Novavax, Zillow, and Ginkgo Bioworks and Encourages Investors to Contact the Firm
-
NOVAVAX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novavax, Inc. and Encourages Investors to Contact the Firm
-
NOVAVAX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novavax, Inc. and Encourages Investors to Contact the Firm
-
NOVAVAX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novavax, Inc. and Encourages Investors to Contact the Firm
-
CTXS, NVAX, OWLT, STNE SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set
-
NOVAVAX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novavax, Inc. and Encourages Investors to Contact the Firm
-
NOVAVAX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novavax, Inc. and Encourages Investors to Contact the Firm
-
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of CTXS, NVAX, OWLT, STNE Investors, Lead Plaintiff Deadlines Set
-
NOVAVAX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novavax, Inc. and Encourages Investors to Contact the Firm
-
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of EAR, NVAX, ONTF, Z Investors, Lead Plaintiff Deadlines Set
-
NOVAVAX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novavax, Inc. and Encourages Investors to Contact the Firm
-
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HMLP, NVAX Investors, Lead Plaintiff Deadlines Set
-
NOVAVAX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novavax, Inc. and Encourages Investors to Contact the Firm
-
Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat
-
Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
-
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
-
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
-
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
-
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
-
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
-
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
-
Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 2021
-
Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
-
Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea
-
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
-
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
-
Novavax and Government of Switzerland Announce Agreement in Principle to Supply COVID-19 Vaccine
-
Novavax Announces Memorandum of Understanding to Produce COVID-19 Vaccine Made in Canada
-
Novavax to Present COVID-19 Vaccine Candidate Data at New York Academy of Science
-
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
-
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
-
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
-
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
-
Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management
-
Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
-
Regulatory Expert Henrietta Ukwu, M.D. Appointed Novavax Chief Regulatory and Quality Officer
-
Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
-
Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine
-
Novavax to Participate in Upcoming Conferences
-
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
-
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
-
Biopharma Executive Rick Crowley Joins Novavax as Chief Operations Officer
-
Biopharma Executive Rick Crowley Joins Novavax as Chief Operations Officer
-
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
-
Novavax Announces Agreement with Government of New Zealand for 10.7 Million Doses of COVID-19 Vaccine
-
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
-
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors
-
Novavax Announces COVID-19 Vaccine Clinical Development Progress
Back to NVAX Stock Lookup
